Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1No longer available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 13110Neoplasms 10462Carcinoma, Non-Small-Cell Lung 6857Prostatic Neoplasms 6258Colorectal Neoplasms 5925Lung Neoplasms 5091Multiple Myeloma 3568Pancreatic Neoplasms 3552Leukemia, Myeloid, Acute 3503Neoplasm Metastasis 3499Carcinoma, Hepatocellular 3264Ovarian Neoplasms 3160Melanoma 3134Stomach Neoplasms 3051Lymphoma 2981Head and Neck Neoplasms 2595Recurrence 2548Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Colonic Neoplasms 2326Brain Neoplasms 2306Lymphoma, Non-Hodgkin 2265Rectal Neoplasms 2186Uterine Cervical Neoplasms 2182Glioblastoma 2010Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1910Squamous Cell Carcinoma of Head and Neck 1875Lymphoma, Follicular 1847Esophageal Neoplasms 1797

Interventions

trametinib 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Progressive Metastatic Castrate Resistant Prostate Cancer × Clear all
NCT07206056 2026-05-08

TulmiSTAR-01

Novartis

Phase 1/2 Recruiting
188 enrolled
Genitourinary

Progressive Metastatic Castrate Resistant Prostate Cancer

NCT03386071 2019-01-16

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Jonsson Comprehensive Cancer Center

No longer available
Genitourinary

Progressive Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡